5-phenyl-3-(3-pyridyl)-2-isoxazoline | 154131-65-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-phenyl-3-(3-pyridyl)-2-isoxazoline
• 英文别名: 3-(3'-pyridinyl)-5-phenyl-2-isoxazoline；Pyridine, 3-(4,5-dihydro-5-phenyl-3-isoxazolyl)-；5-phenyl-3-pyridin-3-yl-4,5-dihydro-1,2-oxazole
• CAS: 154131-65-4
• 化学式: C₁₄H₁₂N₂O
• 分子量: 224.262
• InChiKey: SYCIBYJUPBHOCG-UHFFFAOYSA-N

物化性质

• 沸点：
  374.4±52.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  34.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  苯乙烯 、 N-hydroxynicotinimidoyl chloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以67%的产率得到5-phenyl-3-(3-pyridyl)-2-isoxazoline
  参考文献：
  名称：

  Synthesis of Hydroximoyl Chlorides from Aldoximes and Benzyltrimethylammonium Tetrachloroiodate (BTMA ICl4)

  摘要：

  Benzyltrimethylammonium tetrachloroiodate (BTMA ICl4) acts as a convenient reagent to convert aldoximes to hydroximoyl chlorides by a simple procedure. When an aldoxime is treated with BTMA ICl4 in dichloromethane, the suspension of BTMA ICl4 shortly diasappears as the reaction proceeds. The resulting BTMA ICl2 can he precipitated out by adding diethyl ether. Not only stable aromatic and heteroaromatic hydroximoyl chlorides can be isolated by this method but also rather unstable aliphatic hydroximoyl chlorides can be generated in situ. 1,3-Dipole trapping with a dipolarophile is performed in one flask and in some cases the chlorination is successfully performed in the presence of dipolarophile and triethylamine. Effect of MS 4A has been examined. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)01047-9

文献信息

• Tetrahydropyridine isoxazoline derivatives
  申请人：Warner-Lambert Company

  公开号：US05330994A1

  公开（公告）日：1994-07-19

  A novel compound of the following formulas useful in treating immune-related diseases, inflammation, stoke, epilepsy, dystonias, psychoses, anxiety, and depression: ##STR1##

  以下配方的新化合物可用于治疗免疫相关疾病、炎症、中风、癫痫、肌张力障碍、精神病、焦虑和抑郁症：##STR1##
• Anti-inflammatory compounds
  申请人：Al-Abed Yousef

  公开号：US20070021465A1

  公开（公告）日：2007-01-25

  Compounds of Formula (I), pharmaceutical compositions comprising compounds of Formulae (Ia) or (VII) and a method of treating a subject with an inflammatory cytokine-mediated disorder comprising administering to the subject a compound of Formulae (Ia) or (VIIa). The variables of Formulae (I), (Ia), (VII) and (VIIa) are described herein.
• Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation
  申请人：Newman Walter

  公开号：US20080075728A1

  公开（公告）日：2008-03-27

  Compositions and methods are disclosed for treating a condition characterized by activation of an inflammatory cytokine cascade in a patient. The compositions comprise an HMGB A box and an inhibitor of complement biological activity, and/or an antibody that binds an HMGB polypeptide or biologically active fragment thereof and an inhibitor of complement biological activity, and/or an inhibitor of HMGB receptor binding and an inhibitor of complement biological activity. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of proinflammatory cytokine(s) and/or inhibit the inflammatory cytokine cascade.
• ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION
  申请人：Al-Abed Yousef

  公开号：US20110015231A1

  公开（公告）日：2011-01-20

  Compounds of Formula (I), pharmaceutical compositions comprising compounds of Formulae (I a) or (VII) and a method of treating a subject with an inflammatory cytokine-mediated disorder comprising administering to the subject a compound of Formulae (I a) or (VIIa). The variables of Formulae (I), (I a), (VII) and (VII a) are described herein.
• US5330994A
  申请人：——

  公开号：US5330994A

  公开（公告）日：1994-07-19